This may clear up the issue of when the Phase 2 will complete.
"Northwest is current conducting a Phase 2 clinical trial with DCVax-L in 240 newly diagnosed glioblastoma brain cancer patients. It expects to complete patient recruitment during the fall of 2012 and reach the primary endpoint of progression-free survival within three to six months after that."
It seems like 3-6 months is only for the primary end point and that the secondary end point will be just as important. I would think it would push it out about 1 - 1.5 years after the recruitment ends.